Will BIIB Bounce After Today's Disaster?

Insiders' Blog Commentary : Biogen Idec (Nasdaq: BIIB) is looking like a possible dead-cat bounce play after today's 45% sell-off on the Tysabri fallout. The stock is currently at $36.57/share. We view the litigation risk as minimal. Stock should be worth in low-$40s without the drug.

You May Also Be Interested In

• Biogen (BIIB) PT Raised to $260 at RBC Capital, 'Deep Dive Suggests Upcoming Liti SLE Data Could Start I&I Buildout On Right Path'
• Citi says valuation in this EU airline stock is very attractive
• LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease